Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis

SUMMARY: The MOVEST study evaluated the efficacy and safety of monthly oral ibandronate versus licensed monthly IV ibandronate in Japanese osteoporotic patients. Relative BMD gains after 12 months were 5.22 % oral and 5.34 % IV, showing non-inferiority of oral to IV ibandronate (primary endpoint). N...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, T., Ito, M., Hashimoto, J., Shinomiya, K., Asao, Y., Katsumata, K., Hagino, H., Inoue, T., Nakano, T., Mizunuma, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605968/
https://www.ncbi.nlm.nih.gov/pubmed/26001561
http://dx.doi.org/10.1007/s00198-015-3175-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605968/
https://www.ncbi.nlm.nih.gov/pubmed/26001561
http://dx.doi.org/10.1007/s00198-015-3175-1

Ejemplares similares